SouthState Corp’s United Therapeutics UTHR Stock Holding History

SouthState Corp’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08K	Hold	2	–	–	﹤0.01%	1097
2026 Q1	$1.19K	Buy	2 +1	+100%	+$498	﹤0.01%	1008
2025 Q4	$488	Hold	1	–	–	﹤0.01%	1244
2025 Q3	$420	Sell	1 -1	-50%	-$336	﹤0.01%	1265
2025 Q2	$575	Sell	2 -4	-67%	-$1.2K	﹤0.01%	1407
2025 Q1	$1.85K	Buy	+6	New	+$2.06K	﹤0.01%	1202

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

SouthState Corp's UTHR Position: Q2 2026 in Review

SouthState Corp held its United Therapeutics (UTHR) position steady in Q2 2026 at 2 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1097.

SouthState Corp first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.85K in Q1 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

SouthState Corp held 2 shares of United Therapeutics worth $1.08K as of Q2 2026.
SouthState Corp left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up ﹤0.01% of SouthState Corp's portfolio in Q2 2026, its #1097 holding.
SouthState Corp first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
SouthState Corp's United Therapeutics position peaked at $1.85K in Q1 2025.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.